Hikma Pharmaceuticals Plc Holding(s) in Company (1324W)
06 February 2017 - 11:47PM
UK Regulatory
TIDMHIK
RNS Number : 1324W
Hikma Pharmaceuticals Plc
06 February 2017
Notification of major interests in shares
LONDON, 6 February 2017 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the Hikma Pharmaceuticals
underlying issuer of existing PLC
shares to which the voting
rights are attached
------------------------------- ----------------------
2 Reason for the notification
------------------------------------------ ----
An acquisition or disposal of voting Yes
rights
------------------------------------------ ----
An acquisition or disposal of financial No
instruments which may result in the
acquisition of shares already issues
to which voting rights are attached
------------------------------------------ ----
An event changing the breakdown of voting No
rights
------------------------------------------ ----
Other (please specify): Compliance with No
the Transparency Directive
------------------------------------------ ----
3 Full name of the person subject The Capital Group Companies,
to the notification obligation Inc.
-------------- ------------------------------------------------ ---------------------------------
4 Full name of shareholders Refer to section 9
-------------- ------------------------------------------------ ---------------------------------
5 Date of the Transaction (and 1 February 2017
date on which the threshold
crossed is reached differently)
-------------- ------------------------------------------------ ---------------------------------
6 Date on which the issuer notified 3 February 2017
-------------- ------------------------------------------------ ---------------------------------
7 Threshold that is crossed 10%
-------------- ------------------------------------------------ ---------------------------------
8 Notified details See A, B & C below
-------------- ------------------------------------------------ ---------------------------------
A. Voting rights attached to shares
---------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the
of shares to the triggering triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------ -------------------------------------------------------
Number Number Number Number of voting % of voting
of shares of voting of shares rights rights
rights
-------------- ----------- ----------- ----------- --------------------- -------------------
Direct Direct Indirect Direct Indirect
-------------- ----------- ----------- ----------- ------- ------------ -------- ---------
Ordinary
Shares
(0.10 GBP)
GB00B0LCW083 22,321,334 22,321,334 24,161,334 10.0691%
---------------- ----------- ----------- ----------- ------- ------------ -------- ---------
B. Qualifying Financial instruments
---------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------
Type of Expiration Exercise/Conversion Number of % of voting
financial Date Period/Date voting rights rights
instrument that may be
acquired if
the instrument
if exercised/converted
------------ ----------- -------------------- ------------------------ ------------
- - - - -
------------ ----------- -------------------- ------------------------ ------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
---------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of % of voting
financial Price Date Period/Date voting rights rights
instrument instrument
refers to
------------ --------- ----------- -------------------- --------------- ----------------
Nominal Delta
------------ --------- ----------- -------------------- --------------- -------- ------
- - - - - - -
------------ --------- ----------- -------------------- --------------- -------- ------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
24,161,334 10.0691%
------------------------ -------------------
9 Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable
---------------------------------------------------------------------------------------
Number of Percent
Shares of Outstanding
The Capital Group Companies, Inc. ("CG") holdings 24,161,334 10.0691%
Holdings by CG Management Companies and Funds:
-- Capital Research and Management Company 24,161,334 10.0691%
---------------------------------------------------------------------------------------
Proxy Voting
-----------------------------------------
10 Name of the proxy holder N/A
--- ------------------------------ ----
11 Number of voting rights proxy
holder will cease to hold:
--- ------------------------------ ----
12 Date on which proxy holder
will cease to hold voting
rights:
--- ------------------------------ ----
13 Additional Information
--- -------------------------- --------------------
14 Contact name: Christopher Aquino
--- -------------------------- --------------------
15 Contact telephone number: +001 (213) 615-0469
--- -------------------------- --------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2015, Hikma achieved
revenues of $1,440 million and profit attributable to shareholders
of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUNSURBSAURAR
(END) Dow Jones Newswires
February 06, 2017 07:47 ET (12:47 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024
